dexamethasone sustained-release / EyePoint Pharma - LARVOL DELTA

Multidrug Treatments Investigated in Smoldering Multiple Myeloma (Targeted Oncology) - "Irene Ghobrial, MD...discusses multiple trials and their significance for treating patients with smoldering multiple myeloma (SMM) and newly diagnosed multiple myeloma (NDMM)....Interim results of the MAIA trial in the New England Journal of Medicine concluded that daratumumab led to significantly longer PFS and a 44% lower risk of disease progression or death than lenalidomide/dexamethasone alone. The ITHACA study is ongoing and has not yielded results on isatuximab's efficacy."

Video